
    
      Chidamideï¼Œa novel histone deacetylase inhibitor has been approved for the treatment of
      relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to
      observe the efficacy and safety of Chidamide as Maintenance Treatment After Autologous
      Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk
      Lymphoma
    
  